A brush-like polymer drug delivery system and its preparation method and application
The reaction of small-molecule drugs modified by polydisulfide backbone and amino acids with polybetaine polymers forms a brush-shaped polymer drug delivery system, solving the problems of poor water solubility and toxic side effects of drugs in the prior art, and realizing the target of drugs Directional and deep delivery reduces toxicity and improves therapeutic effects.
Patent Information
- Application Number
- CN202411053143.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-02
AI Technical Summary
The existing drug delivery systems have problems such as poor water solubility, great toxicity and side effects, lack of targeting and pharmacokinetic disorders, especially the difficulty in degrading the polymer main chain and the presence of cytotoxicity of copper salt residues.
Small-molecule drugs modified with polydisulfide main chain and amino acids and polybetaine polymers form a brush-shaped polymer drug delivery system through click reaction or cycloaddition reaction, and use biological functional groups to improve targeting and tissue penetration ability, reducing Toxicity and enhance pharmacokinetics.
It realizes efficient delivery of poor water-soluble drugs into cells, especially in tumor cells, reduces the toxicity of drugs to normal cells, improves the targeting and therapeutic effect of drugs, and improves tumor inhibition effect through biological functional groups. .
Smart Images

Figure CN118557742B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of polymer chemistry and biomedicine, and specifically relates to a brush-shaped polymer drug delivery system and a preparation method and application thereof. Background Art
[0002] Drug development is a long and costly process. Currently, many drugs and active pharmaceutical ingredients (API) have problems such as poor water solubility, severe toxicity, non-targeting, and pharmacodynamic disorders. For example, the anti-tumor drugs that have been approved for marketing include: Doxorubicin (Dox), Gemcitabine (Gem), MonoMethyl auristatin E (MMAE), Lomustine, 5-Fluorouracil, Paclitaxel, etc. In order to solve the above technical problems, the traditional method usually derivatizes the drug and makes it into a preparation, but derivatization involves the selection of functional group modification sites and controlled release, and it is also necessary to design a specific preparation process according to the properties of the specific API, which is cumbersome and complicated.
[0003] In order to improve the targeting of drugs, reduce drug toxicity and side effects, and enhance the therapeutic effect, antibody-drug conjugates (ADC) came into being. Antibody-drug conjugates use the specific binding of antibodies to achieve targeted and controlled release of drugs. As of now, 14 ADC drugs have been approved for marketing. Most of the active ingredients in these ADC drugs are chemotherapy drugs that have been marketed, such as MMAE, calicheamicins (CLM), DX-8951 derivatives (Dxd) and 7-ethyl-10-hydroxycamptothecin (SN-38). However, these ADC drugs still have problems such as high prices, insufficient payloads, and off-target toxicity. Therefore, it is necessary to develop a universal drug delivery system to solve the above technical problems.
[0004] The Chinese patent document with publication number CN104231155A discloses a cholesterol-modified amphiphilic pH-responsive brush copolymer and its preparation and micelle. The copolymer of the invention is composed of a hydrophilic block hydroxyethyl methacrylate, a hydrophobic block methacrylate and a pH-responsive block methacrylate. N , N-Diethylaminoethyl ester is randomly copolymerized, and then combined with hydrophilic block polyethylene glycol methacrylate to obtain a nano-scale micelle system with an inner layer of cholesterol-modified hydrophobic segments, a middle layer of pH-responsive segments, and an outer shell of hydrophilic segments, which can be used to load water-insoluble drugs and more effectively control drug release. However, the micelle polymer involved in the invention has the problem that the main chain is not degradable and is easily enriched in the body to cause toxic side effects; and the ATRP polymer catalyzed by copper salt will have trace copper salt residues, and there is currently no technology that can completely remove it, and the residual copper salt has certain cytotoxicity.
[0005] The Chinese patent document with publication number CN114870014A discloses a multifunctional anti-tumor polymer drug and its preparation method and use. The polymer drug is assembled from a water-soluble brush-structured conjugated polymer in an aqueous solution. The water-soluble brush-structured conjugated polymer has polybenzothiadiazole-fluorene as a conjugated main chain and amide-amine dendritic molecules as side chains. The polymer surface is modified with carbon monoxide donor CORM-401 and polyethylene glycol. It can generate type I and II photodynamics under near-infrared light irradiation to achieve photodynamic therapy of tumors, and can also release carbon monoxide to achieve gas therapy of tumors. However, the conjugated polymer main chain involved in the invention still has the problem of being difficult to degrade. Summary of the invention
[0006] In view of the problems in the prior art that most active pharmaceutical ingredients API have poor water solubility, large toxic and side effects, lack of targeting and poor pharmacokinetics, the present invention provides a brush-like polymer drug delivery system suitable for the delivery of various drugs.
[0007] The specific technical solutions adopted are as follows:
[0008] A brush-like polymer drug delivery system is obtained by a click reaction or a cycloaddition reaction between a polydisulfide backbone, an amino acid-modified small molecule drug and a polybetaine polymer;
[0009] The structural formula of the polydisulfide main chain is:
[0010] ;
[0011] Wherein, x is an integer of 1-500, preferably an integer of 30-200; y is an integer of 1-2000, preferably an integer of 50-500; z is an integer of 1-1000, preferably an integer of 1-10; R2 is a quencher residue, and R3 is selected from any one of the following structural formulas, Indicates the connection location;
[0012] ;
[0013] R1 and R3 are the same, or are methyl or methoxy;
[0014] The structural formula of amino acid modified small molecule drugs is:
[0015] ;
[0016] Wherein, A is a small molecule drug residue; R4 is a functional group capable of undergoing a click reaction or a cycloaddition reaction with R1 or R3, and is selected from any one of the following structural formulas: Indicates the connection location;
[0017] ;
[0018] The structural formula of polybetaine-based compounds is:
[0019] ;
[0020] Wherein, B is a chain transfer agent (RAFT agent) residue; R5 is a functional group capable of undergoing a click reaction or a cycloaddition reaction with R1 or R3, and is selected from any one of the following structural formulas, Indicates the connection location;
[0021] ;
[0022] R6 is a residue of a functional group with biological function, including a folic acid residue, a polyfluoroalkane residue, a maleic acid residue, and a cholesterol residue; m and n respectively represent the average degree of polymerization of the corresponding chain segments, m is an integer of 1-100, and n is a natural number of 0-100; when n=0, it is a polybetaine polymer without a biological functional group; when n is an integer of 1-100, it is a polybetaine polymer containing a biological functional group.
[0023] When the polybetaine polymer contains biological functional groups, it is beneficial to improve the tissue penetration ability or targeting of the brush polymer drug delivery system, and the disease treatment effect is better.
[0024] Preferably, the structural formula of the polybetaine polymer is:
[0025] ;
[0026] Wherein, m is an integer of 1-100, and n is an integer of 1-10.
[0027] The present invention designs the structure of the drug delivery system, and reduces the toxicity of the drug, enhances the targeting of the drug, improves the pharmacokinetics, and solves the problem of poor water solubility of certain small molecule drugs through the reaction between the polydisulfide backbone, amino acid-modified small molecule drugs and the polybetaine macromolecule and the formed brush-like structure, and can be used in the treatment of tumors, cardiovascular diseases, neurological diseases, pathogenic bacteria or viral infections or in the development of vaccines according to the type and amount of the small molecule drugs carried.
[0028] Preferably, the molecular weight of the small molecule drug is 1-8000 Da, including the anti-tumor small molecule drugs monomethyl auristatin E, doxorubicin, gemcitabine, etc.
[0029] Preferably, when the polydisulfide backbone, the amino acid-modified small molecule drug and the polybetaine polymer undergo a click reaction or a cycloaddition reaction, the molar ratio is 1:0.01-1000:0.01-2000, more preferably 1:0.01-1000:0.01-1000, and even more preferably 1:0.1-100:0.1-100.
[0030] The present invention also provides a method for preparing the brush-like polymer drug delivery system, comprising: in an organic solvent system, a polydisulfide main chain and one or more amino acid modified small molecule drugs first undergo a click reaction or a cycloaddition reaction, and then a polybetaine polymer is added to undergo a click reaction or a cycloaddition reaction to prepare the brush-like polymer drug delivery system; when a click reaction occurs, the reaction conditions are 0-60°C and 2-48 h; when a cycloaddition reaction occurs, the reaction conditions are 25-100°C and 1-72 h.
[0031] Furthermore, when a copper-catalyzed click reaction occurs, cuprous salts or copper salts-sodium ascorbate are used as catalysts.
[0032] The synthesis method of the polydisulfide main chain is as follows: under the action of a first promoter and a first catalyst, thioctic acid and a first compound containing a hydroxyl group and an R3 group undergo a dehydration condensation reaction in an organic solvent to prepare a first intermediate; in an oxygen-free environment, a second promoter and polyethylene glycol containing a thiol group and an R1 group react to generate a thiol-containing initiator, under the action of the initiator, the first intermediate undergoes ring-opening polymerization, a quencher is added, and after the reaction is completed, post-treatment is performed to prepare the polydisulfide main chain.
[0033] Preferably, the first accelerator is N,N' -carbonyldiimidazole, the catalyst is 4-dimethylaminopyridine; the reaction conditions of lipoic acid and the first compound containing a hydroxyl group and an R3 group are 0-60°C and 2-48 hours.
[0034] Preferably, the second accelerator is tetramethylguanidine, the conditions for the ring-opening polymerization of the first intermediate are 20-40° C., 1-24 h; and the quencher includes trifluoroethyl acrylate.
[0035] The preparation method of the amino acid modified small molecule drug is as follows: in an organic solvent, the small molecule drug and the protected amino acid undergo a nucleophilic substitution reaction, and then an alkaline substance is added to remove the protecting group to obtain a small molecule drug-amino acid conjugate; the small molecule drug-amino acid conjugate and an activated ester containing an R4 group undergo a nucleophilic substitution reaction to prepare the amino acid modified small molecule drug.
[0036] The protected amino acid is preferably , R7 is an amino protecting group, including 9-fluorenylmethoxycarbonyl protecting group (Fmoc), tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl protecting group (Teoc) and the like.
[0037] Preferably, the alkaline substance added when removing the protecting group is triethylamine or the like.
[0038] When preparing small molecule drug-amino acid conjugates, the reaction temperature is 0-100°C and the reaction time is 0.5-48 h; when the small molecule drug-amino acid conjugates and the activated ester containing the R4 group undergo nucleophilic substitution reaction, the reaction temperature is 0-80°C and the reaction time is 0.5-72 h.
[0039] The preparation method of the polybetaine polymer comprises the following steps: a chain transfer reagent, an azobisisobutyronitrile initiator and a betaine monomer are used to react to obtain a second intermediate, or a chain transfer reagent, an azobisisobutyronitrile initiator, a functional monomer containing an R6 group and a betaine monomer are used to react to obtain a second intermediate; after the second intermediate is subjected to n-propylamine to remove the thiocarbonyl group, an addition reaction is carried out with a methacrylate compound containing an R5 group to prepare the polybetaine polymer.
[0040] Preferably, the chain transfer agent can be selected from any one of 4-cyano-4-(thiobenzoyl)pentanoic acid, 2-[dodecylthio(thiocarbonyl)thio]-2-methylpropionic acid, 4-((((2-carboxyethyl)thio)thiocarbonyl)thio)-4-cyanopentanoic acid, 4-cyano-4-[[(propylthio)thiomethyl]thio]pentanoic acid, 2-(ethylmercaptothioformylthio)-2-methylpropionic acid, 4-cyano-4-(((ethylthio)thiocarbonyl)thio)pentanoic acid, and the like.
[0041] Functional monomers include acrylate derivatives of polyfluoroalkanes, acrylate derivatives of folic acid, acrylate derivatives of maleic acid, acrylate derivatives of cholesterol, and the like.
[0042] The reaction conditions for preparing the second intermediate are preferably 40-100° C. and the reaction time is 0.5-72 h.
[0043] Preferably, the conditions for removing the thiocarbonyl group from the second intermediate are 20-40° C. for 1-24 h; after removing the thiocarbonyl group, the conditions for the addition reaction with the methacrylate compound containing the R5 group are 20-40° C. for 0.5-72 h.
[0044] The present invention also provides application of the brush-like polymer drug delivery system in the field of drug delivery.
[0045] The present invention also provides the use of the brush-like polymer drug delivery system in preparing disease treatment products.
[0046] The present invention also provides the use of the brush-like polymer drug delivery system in the preparation of disease prevention products.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] (1) The drug delivery system provided by the present invention can efficiently deliver drugs with poor water solubility and difficulty entering cells into cells, especially when entering glutathione-rich cells such as tumor cells, it can achieve rapid release of drugs. The process route for the synthesis of the drug delivery system has not been reported in the prior art.
[0049] (2) When the brush-like polymer drug delivery system is synthesized from a polybetaine polymer containing a biological functional group (polyfluoroalkane residue), it can effectively enhance the depth of the drug delivery system into solid tumors and exert a better tumor inhibition effect.
[0050] (3) The method of the present invention utilizes amino acid-modified small molecule drugs, which greatly broadens the range of drug selection and has good universality. The amino acid-modified small molecule drugs are further grafted onto the polydisulfide backbone chain by covalent bonding, which has strong binding force. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 The average hydration diameters and distribution statistics of the brush-like polymer drug delivery systems 17, 23, and 27 prepared in Examples 1, 4, and 5, respectively.
[0052] Figure 2 They are infrared spectra of the polydisulfide backbone 4, the polydisulfide backbone 4 coupled with MMAE, and the brush-like polymer drug delivery system 17 prepared in Example 1, respectively. -N3 represents an azide group.
[0053] Figure 3They are infrared spectra of polydisulfide backbone 4, polydisulfide backbone 4 coupled with Dox, and brush-like polymer drug delivery system 23 prepared in Example 4, respectively. -N3 represents an azide group.
[0054] Figure 4 They are infrared spectra of polydisulfide backbone 4, polydisulfide backbone 4 coupled with Gem, and brush-like polymer drug delivery system 27 prepared in Example 5, respectively. -N3 represents an azide group.
[0055] Figure 5 This is a graph showing the results of a dithiothreitol (DTT) degradation experiment of the brush-like polymer drug delivery system 17 prepared in Example 1.
[0056] Figure 6 These are statistical graphs of the brush-like polymer drug delivery systems 17 and 18 prepared in Example 1 entering mouse breast cancer (4T1) cells at different concentrations.
[0057] Figure 7 The statistical graphs of the cytotoxicity of brush-like polymer drug delivery systems 17, 23, 27 prepared in Examples 1, 4, and 5 and the corresponding free drugs to human umbilical vein endothelial cells (HUVEC) are shown.
[0058] Figure 8 The statistical graphs of the cytotoxicity of brush-like polymer drug delivery systems 17, 23, 27 prepared in Examples 1, 4, and 5 and the corresponding free drugs to mouse breast cancer (4T1) and human ovarian adenocarcinoma (SKOV3) cells are shown.
[0059] Fig. 9 The following are tumor tissue sections of the brush-like polymer drug delivery systems 17 and 18 prepared in Example 1 entering a solid tumor. The scale is 500 μm.
[0060] Fig.10 This is a tumor tissue section image of the brush-like polymer drug delivery system 23 prepared in Example 4 entering a solid tumor, with a scale of 500 μm.
[0061] Fig.11 This is a diagram showing the tumor inhibition effect of the brush-like polymer drug delivery system 17 prepared in Example 1. DETAILED DESCRIPTION
[0062] The present invention is further illustrated below in conjunction with the examples and accompanying drawings. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The operating methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0063] Example 1
[0064] (1) Synthesis of Lipoic Acid Derivative Monomers
[0065] ;
[0066] Weigh 30.0 g (compound 1, 0.145 mol) of lipoic acid into a 500 ml round-bottom flask, add 300 ml of anhydrous dichloromethane (DCM) to fully dissolve, and add 25.9 g (0.160 mol) of N,N' -carbonyldiimidazole (CDI), stirred at room temperature for 30 minutes, then added 13.2 g (0.131 mol) 3-azidopropanol (compound 2), followed by 1.8 g (14.5 mmol) 4-dimethylaminopyridine (DMAP), kept at room temperature overnight, added 200 ml water to wash the organic phase, collected the organic phase, dried over anhydrous sodium sulfate, and dried under reduced pressure, added 200 ml ether to dissolve the residual sample, filtered to remove insoluble matter, washed the mother liquor twice with 200 ml water, collected the organic phase, dried over anhydrous sodium sulfate, dried under reduced pressure, and pumped dry with an oil pump to obtain 34.4 g yellow oily compound 3 with a yield of 82%.
[0067] The H NMR spectrum data of compound 3 is: 1 H NMR (400 MHz, CDCl3) δ 4.16 (t, J = 6.0Hz, 2H), 3.62–3.52 (m, 1H), 3.39 (t, J = 6.8 Hz, 2H), 3.25–3.05 (m, 2H), 2.52–2.41 (m, 1H), 2.33 (t, J = 7.2 Hz, 2H), 1.98–1.85 (m, 3H), 1.77–1.61 (m, 4H), 1.56–1.39 (m, 2H).
[0068] (2) Synthesis of polydisulfide backbone
[0069] ;
[0070] Weigh 30.4 mg (0.02 mmol) of azidopolyethylene glycol thiol (N3-PEG 2000-SH) was placed in a 1.5 ml centrifuge tube. Under an anaerobic environment, 300 μL of anhydrous tetrahydrofuran (THF) was used to dissolve it, and then 1.9 μL (0.02 mmol) of tetramethylguanidine (Me4-guanidine) was added. The solution became turbid after vortexing for 1 minute. The turbid solution was sucked up once with a pipette and quickly injected into a tetrahydrofuran (500 μL) solution containing 800 μL (3.04 mmol) of compound 3. After vortexing for 5 minutes, the reaction was stirred at room temperature for 2 hours. 39 μL (0.30 mmol) of trifluoroethyl acrylate was added to quench the reaction. After stirring at room temperature for 2 hours, the reaction solution was added dropwise to 30 ml of ether for precipitation. The supernatant was discarded after vortexing and centrifugation. The residual white solid was dissolved with a small amount of dichloromethane and then added dropwise to 30 ml of ether for precipitation. The precipitation was repeated 5 times and then drained to obtain 630 mg of colorless slurry polydisulfide polymer main chain product 4 (Poly(LpN3)) with a yield of 72%.
[0071] The H NMR spectrum data of the polydisulfide backbone 4 is: 1 H NMR (400 MHz, CDCl3) δ 4.16 (t, J =6.4 Hz, 2H), 3.64 (s, 1H), 3.40 (t, J = 6.8 Hz, 2H), 2.90–2.66 (m, 3H), 2.34(t, J = 7.2 Hz, 2H), 2.10–1.83 (m, 4H), 1.72–1.59 (m, 4H), 1.55–1.39 (m, 2H).
[0072] The NMR fluorine spectrum data of the polydisulfide backbone 4 is: 19 F NMR (376 MHz, CDCl3) -73.68.
[0073] (3) Synthesis of polybetaine polymer
[0074] (3.1) Synthesis of polybetaine polymers containing biological functional groups
[0075] ;
[0076] 40 μL (0.31 mmol) of trifluoro monomer compound 5, 87.0 mg (0.31 mmol) of chain transfer agent 6 (4-cyano-4-(thiobenzoyl)valeric acid) and 10.2 mg (0.06 mmol) of azobisisobutyronitrile (AIBN) were weighed into a 1.5 ml glass sample bottle, and a stirring rotor and 500 μL of anhydrous ethanol (EtOH) were added to fully dissolve. The mixture was heated to 70 °C and stirred for 20 minutes under anaerobic conditions. The reaction solution was then injected into a mixed solution of ethanol (2.6 ml) and water (3.0 ml) containing 1.90 g (7.80 mmol) of betaine monomer compound 7, heated to 70 °C for 3 hours, cooled to room temperature and stirred under aerobic conditions to quench the reaction. The mixture was dialyzed against pure water for 2 days and freeze-dried to obtain 1.5 g of red solid polymer 8 with a yield of 79%.
[0077] The H NMR spectrum data of product 8 is: 1 H NMR (400 MHz, CDCl3) δ 8.13–7.85 (m, 2H),7.76–7.41 (m, 3H), 3.76–3.44 (s, 51H), 3,41–2.97 (m, 251H), 2.94–2.81 (s,23H), 2.76–2.52 (s, 51H), 2.37–2.17 (m, 6H), 2.15–1.58 (m, 108H), 1.45–0.74 (m, 89H).
[0078] The NMR fluorine spectrum data of product 8 is: 19 F NMR (376 MHz, CDCl3) -72.76, -73.54, -76.80.
[0079] Weigh 1.0 g of red solid polymer 8 into a 10 ml glass sample bottle, dissolve it in a mixed solvent of dimethyl sulfoxide (DMSO, 2.0 ml) and methanol (MeOH, 2.0 ml) under anaerobic conditions, add 677 μL (8.23 mmol) of n-propylamine and react at room temperature for 2 hours. The reaction solution changes from the original red to colorless and transparent. Add 94.2 mg (0.33 mmol) of tris(2-chloroethyl) phosphate (TCEP), continue to react for 30 minutes, then add 897.1 mg (4.12 mmol) of compound 9, react at room temperature under anaerobic conditions for 4 hours, precipitate in ethyl acetate, centrifuge, dissolve the solid in water and dialyze for 24 hours, and freeze-dry to obtain 920 mg of white solid polybetaine polymer 10, with a yield of 92%.
[0080] The H NMR spectrum data of compound 10 is: 1H NMR (400 MHz, CDCl3) δ 4.09 (m, 2H), 3.56 (s, 50H), 3.41–2.98 (m, 228H), 2.84–2.22 (m, 102H), 2.10–1.62 (m, 108H), 1.45–0.72 (m, 100H).
[0081] (3.2) Synthesis of polybetaine polymers without biological functional groups
[0082] ;
[0083] 1.9 g (8.00 mmol) of betaine monomer compound 7, 89.3 mg (0.32 mmol) of chain transfer agent 6 and 10.5 mg (0.06 mmol) of azobisisobutyronitrile (AIBN) were weighed into a 10 ml glass sample bottle. Under anaerobic conditions, a stirring rotor and 5.0 ml of deionized water were added. After sufficient dissolution, the mixture was heated to 70 °C and stirred for 2 hours. The mixture was cooled to room temperature and stirred under aerobic conditions to quench the reaction. The mixture was dialyzed with pure water for 2 days and freeze-dried to obtain 1.6 g of red solid polymer 11 with a yield of 84%.
[0084] The H NMR spectrum data of polymer 11 is: 1 H NMR (400 MHz, CDCl3) δ 8.10–7.88 (m,2H), 7.76–7.40 (m, 3H), 3.64–3.46 (s, 52H), 3,42–2.94 (m, 277H), 2.93–2.81(s, 23H), 2.74–2.57 (s, 52H), 2.35–1.58 (m, 123H), 1.49–0.69 (m, 98H).
[0085] Weigh 1.0 g of red solid polymer 11 into a 10 ml glass sample bottle, dissolve it in a mixed solvent of DMSO (2.0 ml) and methanol (2.0 ml) under anaerobic conditions, add 651 μL (7.91 mmol) of n-propylamine and react at room temperature for 2 hours. The reaction solution changes from the original red to colorless and transparent. Add 90.5 mg (0.32 mmol) of tris(2-chloroethyl) phosphate (TCEP), continue to react for 30 minutes, then add 862.6 mg (3.96 mmol) of compound 9, react at room temperature under anaerobic conditions for 4 hours, precipitate in ethyl acetate, centrifuge, dissolve the solid in water and dialyze for 24 hours, and freeze-dry to obtain 900 mg of white solid 12 with a yield of 90%.
[0086] The H NMR spectrum data of compound 12 is:1 H NMR (400 MHz, CDCl3) δ 4.13–4.08 (m,2H), 3.56 (s, 52H), 3.41–3.01 (m, 282H), 3.87 (s, 52H), 2.73–2.61 (m, 52H), 2.55–1.59 (m, 166H), 1.43–0.75 (m, 120H).
[0087] (4) Synthesis of amino acid modified small molecule drugs
[0088] ;
[0089] 153.4 mg (0.20 mmol) of commercial compound 13 and 143.4 mg (0.20 mmol) of small molecule drug monomethyl auristatin E (MMAE) were weighed into a 5 ml glass sample bottle, and 1.5 ml of anhydrous N,N-dimethylformamide (DMF) was added to dissolve under nitrogen protection. 25.8 mg (0.20 mmol) N,N -diisopropylethylamine (DIPEA), stirred at room temperature for 2 hours, added 3.00 mmol triethylamine (Et3N) and continued to react for 2 hours, the reaction solution was added dropwise to 40 ml anhydrous ether for precipitation, centrifuged, the supernatant was discarded, the residual solid (compound 14) was dried under reduced pressure and dissolved in 2 ml ultra-dry DMF, 58.2 mg (0.20 mmol) of compound 15 and 25.8 mg (0.20 mmol) were added N,N -diisopropylethylamine (DIPEA), react at room temperature for 3 hours, add the reaction solution dropwise into 40 ml of anhydrous ether for precipitation, centrifuge, discard the supernatant, and the residual solid is purified by silica gel column chromatography ( V DCM : V MeOH = 50:1→5:1) was separated and purified to obtain 156 mg of white solid compound 16 (amino acid modified small molecule drug, BCN-VC-MMAE) with a yield of 60%.
[0090] The H NMR spectrum data of compound 16 is: 1H NMR (400 MHz, CDCl3) δ 9.85–9.35 (m,1H), 7.99–7.64 (m, 1H), 7.60–7.47 (m, 2H), 7.36–7.27 (m, 3H), 7.24–7.16 (m,2H), 7.07–6.77 (m, 1H), 6.66–6.38 (m, 1H), 6.03–5.67 (m, 2H), 5.26–4.46 (m,8H), 4.29–3.66 (m, 8H), 3.47–2.71 (m, 18H), 2.47–1.62 (m, 18H), 1.53–1.14 (m,11H), 1.06–0.57 (m, 30H).
[0091] (5) Construction of brush polymer drug delivery system
[0092] ;
[0093] Weigh 5 mg (0.017 mmol) of polydisulfide backbone 4 into a 2 ml centrifuge tube, dissolve it in 200 μL of anhydrous DMSO, then add 4.49 mg (3.46 μmol) of compound 16BCN-VC-MMAE in DMSO solution, shake at room temperature for 4 hours, add 400 μL of anhydrous methanol, mix well, and add 101 mg (0.017 mmol) of fluorinated polybetaine polymer 10 (or add 105 mg, 0.017 mmol of non-fluorinated polybetaine polymer 12) solution ( V DMSO : V MeOH = 1:1), click-reacted with the remaining azide groups in the polydisulfide backbone 4 for 12 h, dialyzed with a 10K dialysis membrane (molecular weight cutoff of 8 kDa-10 kDa) for 24 h at room temperature overnight, and freeze-dried to obtain 90 mg of a brush-like polymer drug delivery system 17 containing polyfluoroalkane functional groups (or 93 mg of a brush-like polymer drug delivery system 18 without polyfluoroalkane functional groups), with a yield of 96%.
[0094] Example 2
[0095] The preparation method of the brush-like polymer drug delivery system in this embodiment is different from that in Embodiment 1 only in that the polydisulfide backbone 19 is prepared according to the following method, and the polymer 10 containing polyfluorinated functional groups is selected as the polybetaine; the other process parameters are the same.
[0096] ;
[0097] Weigh 86.9 mg (0.04 mmol) of azidopolyethylene glycol thiol (N3-PEG 2000 -SH) was placed in a 1.5 ml centrifuge tube. Under an anaerobic environment, it was dissolved in 400 μL of anhydrous tetrahydrofuran (THF), and then 5.5 μL (0.04 mmol) of tetramethylguanidine was added. The solution became turbid after vortexing for 1 minute. The turbid solution was sucked up once with a pipette and quickly injected into a tetrahydrofuran (400 μL) solution containing 800 μL (3.04 mmol) of compound 3. After vortexing for 5 minutes, the mixture was stirred at room temperature for 2 hours. 101 μL (0.80 mmol) of trifluoroethyl acrylate was added. After stirring at room temperature for 2 hours, the reaction solution was added dropwise to 30 ml of ether for precipitation. The supernatant was discarded after vortexing and centrifugation. The residual white solid was dissolved in dichloromethane and then added dropwise to 30 ml of ether for precipitation. The precipitation was repeated 5 times and then drained to obtain 650 mg of colorless slurry polydisulfide backbone 19 with a yield of 74%.
[0098] The H NMR spectrum data of the polydisulfide backbone 19 is: 1 H NMR (400 MHz, CDCl3) δ 4.16 (t, J =6.4 Hz, 2H), 3.64 (s, 3H), 3.40 (t, J = 6.4 Hz, 2H), 2.89–2.70 (m, 3H), 2.34(t, J = 7.2 Hz, 2H), 2.08–1.86 (m, 4H), 1.71–1.38 (m, 6H).
[0099] The NMR fluorine spectrum data of the polydisulfide backbone 19 is: 19 F NMR (376 MHz, CDCl3) -73.55.
[0100] Example 3
[0101] The preparation method of the brush-like polymer drug delivery system in this embodiment is different from that in Embodiment 1 only in that the polydisulfide backbone 20 is prepared according to the following method, and the polymer 10 containing polyfluorinated functional groups is selected as the polybetaine; the other process parameters are the same.
[0102] ;
[0103] Weigh 12.2 mg (6.08 μmol) of azidopolyethylene glycol thiol (N3-PEG 2000-SH) was placed in a 1.5 ml centrifuge tube. Under an anaerobic environment, it was dissolved in 200 μL of anhydrous tetrahydrofuran (THF), and then 0.8 μL (6.08 μmol) of tetramethylguanidine was added. The solution was vortexed for 1 minute, and the solution became turbid. The turbid solution was sucked up once with a pipette and quickly injected into a tetrahydrofuran (600 μL) solution containing 800 μL (3.04 mmol) of compound 3. After vortexing for 5 minutes, it was stirred at room temperature for 2 hours. 15 μL (0.12 mmol) of trifluoroethyl acrylate was added. After stirring at room temperature for 2 hours, the reaction solution was added dropwise to 30 ml of ether for precipitation. After vortexing and centrifugation, the supernatant was discarded. The residual white solid was dissolved in dichloromethane and then added dropwise to 30 ml of ether for precipitation. The precipitation was repeated 5 times and then drained to obtain 640 mg of colorless slurry polydisulfide polymer backbone 20 with a yield of 73%.
[0104] The H NMR spectrum data of the polydisulfide backbone 20 is: 1 H NMR (400 MHz, CDCl3) δ 4.16 (t, J =6.4 Hz, 6H), 3.64 (s, 1H), 3.40 (t, J = 6.8 Hz, 6H), 2.90–2.66 (m, 9H), 2.34(t, J = 7.2 Hz, 6H), 2.09–1.84 (m, 12H), 1.73–1.60 (m, 12H), 1.54–1.37 (m, 6H).
[0105] The NMR fluorine spectrum data of the polydisulfide backbone 20 is: 19 F NMR (376 MHz, CDCl3) -73.72.
[0106] Example 4
[0107] The preparation method of the brush-like polymer drug delivery system in this embodiment is different from that in Embodiment 1 only in that the amino acid-modified doxorubicin small molecule drug BCN-VC-Dox is prepared according to the following method;
[0108] ;
[0109] 153.4 mg (0.20 mmol) of commercial compound 13 and 108.6 mg (0.20 mmol) of doxorubicin (Dox) were weighed into a 5 ml glass sample bottle, and 1.5 ml of anhydrous DMF was added to dissolve under nitrogen protection. 25.8 mg (0.20 mmol) N,N-diisopropylethylamine (DIPEA), stirred at room temperature for 2 hours, added 3.00 mmol triethylamine and continued to react for 2 hours, the reaction solution was added dropwise to 40 ml anhydrous ether for precipitation, centrifuged, the supernatant was discarded, the residual solid was dried under reduced pressure and dissolved in 2 ml ultra-dry DMF, 58.2 mg (0.20 mmol) of compound 15 and 25.8 mg (0.20 mmol) were added N,N -diisopropylethylamine (DIPEA), react at room temperature for 3 hours, add the reaction solution dropwise into 40 ml of anhydrous ether for precipitation, centrifuge, discard the supernatant, and the residual solid is purified by silica gel column chromatography ( V DCM : V MeOH = 50:1→5:1) was separated and purified to obtain 124 mg of red solid compound 22 (amino acid-modified small molecule drug, BCN-VC-Dox) with a yield of 55%.
[0110] The H NMR spectrum data of compound 22 is: 1 H NMR (400 MHz, CDCl3) δ 14.01 (s, 1H), 13.26 (s, 1H), 9.98 (s, 1H), 7.99 (d, J = 7.6 Hz,1H), 7.91–7.88 (m, 1H), 7.68–7.59 (m, 1H), 7.50 (d, J = 8.0 Hz,1H), 7.21 (d, J = 8.4 Hz,1H), 7.09 (d, J = 8.8Hz,1H), 6.81 (d, J = 8.0 Hz,1H), 5.99–5.90 (m, 1H), 5.53–5.29 (m, 3H), 5.23–5.14 (m, 1H), 4.94–4.81 (m, 3H), 4.68 (d, J = 6.0 Hz,1H), 4.53 (d, J= 6.0 Hz,1H), 4.39–4.32 (m, 1H), 4.14–4.07 (m, 1H), 3.96 (s, 2H), 3.87–3.81 (m, 2H), 3.71–3.63 (m, 2H), 3.08–2.81 (m, 7H), 2.30–1.98 (m, 7H), 1.94–1.87 (m, 1H), 1.84–1.76 (m, 1H), 1.72–0.98 (m, 16H), 0.92–0.72 (m, 6H), 0.67–0.57 (m, 2H).
[0111] The polybetaine selected polymer 10 containing polyfluorinated functional groups or polybetaine polymer 12 without fluorine. When the polybetaine selected polymer 10 containing polyfluorinated functional groups, the amino acid-modified doxorubicin small molecule drug BCN-VC-Dox was used to construct a brush-like polymer drug delivery system 23. When the polybetaine selected polymer 12 without polyfluorinated functional groups, the amino acid-modified doxorubicin small molecule drug BCN-VC-Dox was used to construct a brush-like polymer drug delivery system 24. Other process parameters were the same (the molar ratio of the polydisulfide backbone, the amino acid-modified small molecule drug and the polybetaine polymer was kept at 1:0.2:1). The yield of the brush-like polymer drug delivery system 23 was 94%.
[0112] Example 5
[0113] The preparation method of the brush-like polymer drug delivery system in this embodiment is different from that in Embodiment 1 only in that the amino acid-modified gemcitabine small molecule drug BCN-VC-Gem is prepared according to the following method;
[0114] ;
[0115] 153.4 mg (0.20 mmol) of commercial compound 13 and 52.6 mg (0.20 mmol) of gemcitabine (Gem) were weighed into a 5 ml glass sample bottle, and 1.5 ml of anhydrous DMF was added to dissolve under nitrogen protection. 25.8 mg (0.20 mmol) N,N -diisopropylethylamine (DIPEA), stirred at room temperature for 2 hours, added 3.00 mmol triethylamine and continued to react for 2 hours, the reaction solution was added dropwise to 40 ml anhydrous ether for precipitation, centrifuged, the supernatant was discarded, the residual solid was dried under reduced pressure and dissolved in 2 ml ultra-dry DMF, 58.2 mg (0.20 mmol) of compound 15 and 25.8 mg (0.20 mmol) were added N,N-diisopropylethylamine (DIPEA), react at room temperature for 3 hours, add the reaction solution dropwise into 40 ml of anhydrous ether for precipitation, centrifuge, discard the supernatant, and the residual solid is purified by silica gel column chromatography ( V DCM : V MeOH = 50:1→5:1) after separation and purification, 81 mg of red solid compound 26 was obtained with a yield of 48%.
[0116] The H NMR spectrum data of compound 26 is: 1 H NMR (400 MHz, CDCl3) δ 10.36 (s, 1H),8.16 (d, J = 7.6 Hz, 1H), 7.73–7.60 (m, 4H), 7.46–7.31 (m, 3H), 7.15 (d, J = 8.8Hz, 1H), 6.40–6.27 (m, 1H), 6.21 (t, J = 9.2 Hz, 1H), 5.87 (d, J = 7.6 Hz, 1H),5.63–5.44 (m, 2H), 5.44–5.32 (m, 1H), 5.31–5.07 (m, 3H), 4.48–4.38 (m, 1H),4.19–4.11 (m, 1H), 3.96–3.79 (m, 3H), 3.78–3.57 (m, 3H), 3.04–2.89 (m, 2H), 2.42–2.26 (m, 2H), 2.25–2.12 (m, 2H), 2.12–1.90 (m, 3H), 1.78–1.68 (m, 1H),1.66–1.54 (m, 1H), 1.50–1.21 (m, 4H), 0.89–0.80 (m, 6H), 0.77–0.50 (m, 3H).
[0117] Polybetaine selected a polymer 10 containing a polyfluorinated functional group, and used the amino acid-modified gemcitabine small molecule drug BCN-VC-Gem to construct a brush-like polymer drug delivery system 27. Other process parameters were the same (keeping the molar ratio of the polydisulfide backbone, amino acid-modified small molecule drug and polybetaine polymer at 1:0.2:1), and the yield of the brush-like polymer drug delivery system 27 was 93%.
[0118] Sample analysis
[0119] (1) Performance characterization
[0120] Figure 1 The average hydration diameter and its distribution diagram of brush-like polymer drug delivery systems 17, 23, and 27 of Examples 1, 4, and 5 detected by dynamic light scattering. The surface Zeta potentials of brush-like polymer drug delivery systems 17, 23, and 27 are 2.97 mV, 2.31 mV, and 2.00 mV, respectively. Due to the differences in hydrophilicity and hydrophobicity of different small molecule drugs, there are slight differences in the size of the brush-like polymer drug delivery system, but the average hydration diameter is about 30 nm, and the surface potential of the nanoparticles is close to neutrality.
[0121] Figure 2 The infrared spectra of the brush-like polymer drug delivery system 17 prepared in Example 1 are respectively the polydisulfide backbone 4, the polydisulfide backbone 4 coupled with MMAE, and the brush-like polymer drug delivery system 17 prepared in Example 1. The wave number is 2100 cm -1 The absorption intensity of the azide functional group at the α-D-type ... -1 When the azide absorption peak at completely disappears, it indicates that the brush polymer 17 is successfully prepared; Figure 3 and Figure 4 Similarly, the successful preparation of the brush-like polymer drug delivery system 23 and the brush-like polymer drug delivery system 27 in Example 4 are respectively indicated.
[0122] (2) Degradation experiment
[0123] Figure 5 The dithiothreitol (DTT) degradation experiment effect diagram of the brush polymer drug delivery system 17. The results show that the brush polymer delivery system prepared by the present invention can achieve 90% degradation within 1 hour and complete degradation within 2 hours under the action of DTT, which proves the degradability of the brush polymer delivery system prepared by the present invention in the tumor-rich reducing environment.
[0124] (3) Cell uptake experiment
[0125] Figure 6 Flow cytometric graphs showing the uptake of brush polymer drug delivery systems 17 and 18 prepared by the present invention by mouse breast cancer (4T1) cells. The results show that the brush polymer drug delivery systems prepared by the present invention can enter tumor cells well at both low and high concentrations, and the brush polymer drug delivery systems carrying polyfluorinated functional groups are easier to enter tumor cells than the brush polymer drug delivery systems not carrying polyfluorinated functional groups.
[0126] (4) Cytotoxicity assay
[0127] Figure 7The flow cytometric graphs of the toxicity study of brush-like polymer drug delivery systems 17, 23, and 27 of Examples 1, 4, and 5 on human umbilical vein endothelial cells (HUVEC). The results show that even at a drug concentration of 10 μM, the brush-like polymer drug delivery system coupled with gemcitabine and doxorubicin still exhibits almost no toxicity to normal cells; in contrast, under the action of the same concentration of free small molecule drugs, the survival rate of HUVEC cells is below 20%. Even for the highly toxic monomethyl auristatin E bulk drug, the brush-like polymer drug delivery system prepared by the present invention can reduce its toxicity to normal cells to less than 1 / 50 of the free small molecule drug. These results fully demonstrate that the brush-like polymer drug delivery system prepared by the present invention can greatly reduce the toxic side effects of drugs on normal cells.
[0128] Figure 8 The flow cytometric graphs of the toxicity study of brush-like polymer drug delivery systems 17, 23, and 27 of Examples 1, 4, and 5 on mouse breast cancer (4T1) and human ovarian adenocarcinoma (SKOV3) cells are shown. The results show that due to the presence of a large amount of glutathione in tumor cells, under the action of this reducing peptide, the brush-like polymer drug delivery system can be completely degraded and release the drug to kill tumor cells.
[0129] (5) Entering into in-depth experiments on solid tumors
[0130] Fig. 9 In order to use cyanine dye Cy5 (CAS: 146368-15-2) as a fluorescent marker, the brush-like polymer drug delivery system 18 and 17 without / with polyfluorinated functional groups in Example 1 entered the tumor tissue section of the solid tumor 24 hours after injection into the mouse. The results show that the polymer without polyfluorinated functional groups is difficult to enter the tumor tissue and the killing effect on the tumor is not ideal; while the polymer with polyfluorinated functional groups can better enter the tumor tissue and have a better killing effect on the tumor.
[0131] Fig.10 Using cyanine dye Cy7 (CAS: 943298-08-6) as a fluorescent marker, the brush-like polymer drug delivery system 23 prepared in Example 4 entered the tumor tissue section of a solid tumor 24 hours after injection into mice. Using a confocal microscope, the presence of the anti-tumor drug doxorubicin can be clearly observed inside the tumor tissue; this indicates that the polymer carrying a polyfluorinated functional group can better deliver the drug into the tumor tissue.
[0132] (6) Tumor inhibition experiment
[0133] Fig.11This is a diagram showing the inhibitory effect of the brush-like polymer drug delivery system 17 on tumor inhibition. The size of solid tumors after administration of the brush-like polymer drug delivery system 17 was measured. The results fully demonstrate that the brush-like polymer drug delivery system prepared by the present invention can effectively inhibit tumor growth, and the effect is more obvious than that of VC-MMAE. VC-MMAE is a modified small molecule drug with a structural formula of , indicating that the brush-like polymer drug delivery system prepared by the present invention has great clinical transformation value.
[0134] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A brush polymer drug delivery system, characterized in that: It is obtained by click reaction or cycloaddition reaction of a polydisulfide backbone, an amino acid-modified small molecule drug and a polybetaine polymer; The structural formula of the polydisulfide main chain is: ; Wherein, x is an integer of 1-500, y is an integer of 1-2000, and z is an integer of 1-1000; R2 is a quencher residue, and R3 is selected from any one of the following structural formulas, Indicates the connection location; ; R1 and R3 are the same, or are methyl or methoxy; Amino acid modified small molecule drugs are represented by: ; Wherein, A is a small molecule drug residue; R4 is a functional group capable of undergoing a click reaction or a cycloaddition reaction with R1 or R3, and is selected from any one of the following structural formulas: Indicates the connection location; ; The structural formula of polybetaine polymer is: ; Wherein, B is a chain transfer agent residue; R5 is a functional group capable of undergoing a click reaction or a cycloaddition reaction with R1 or R3, and is selected from any one of the following structural formulas: Indicates the connection location; ; R6 is a residue of a functional group with biological function, including a folic acid residue, a polyfluoroalkane residue, a maleic acid residue, and a cholesterol residue; m and n respectively represent the average degree of polymerization of the corresponding chain segments, m is an integer of 1-100, and n is a natural number of 0-100.
2. The brush-like polymer drug delivery system according to claim 1, characterized in that: The structural formula of polybetaine polymer is: ; Wherein, m is an integer of 1-100, and n is an integer of 1-10.
3. The brush-like polymer drug delivery system according to claim 1, characterized in that: The molar ratio of the polydisulfide main chain, the amino acid modified small molecule drug and the polybetaine macromolecule is 1:0.01-1000:0.01-2000.
4. The method for preparing the brush-like polymer drug delivery system according to any one of claims 1 to 3, characterized in that: In an organic solvent system, a polydisulfide main chain and one or more amino acid modified small molecule drugs first undergo a click reaction or a cycloaddition reaction, and then a polybetaine polymer is added to undergo a click reaction or a cycloaddition reaction to prepare the brush-like polymer drug delivery system; when a click reaction occurs, the reaction conditions are 0-60°C, 2-48 h; when a cycloaddition reaction occurs, the reaction conditions are 25-100°C, 1-72 h.
5. The method for preparing the brush-like polymer drug delivery system according to claim 4, characterized in that: The synthesis method of the polydisulfide main chain is as follows: under the action of a first promoter and a first catalyst, thioctic acid and a first compound containing a hydroxyl group and an R3 group undergo a dehydration condensation reaction in an organic solvent to prepare a first intermediate; in an oxygen-free environment, a second promoter and polyethylene glycol containing a thiol group and an R1 group react to generate a thiol-containing initiator, under the action of the initiator, the first intermediate undergoes ring-opening polymerization, a quencher is added, and after the reaction is completed, post-treatment is performed to prepare the polydisulfide main chain.
6. The method for preparing the brush-like polymer drug delivery system according to claim 4, characterized in that: The preparation method of the amino acid modified small molecule drug is as follows: in an organic solvent, the small molecule drug and the protected amino acid undergo a nucleophilic substitution reaction, and then an alkaline substance is added to remove the protecting group to obtain a small molecule drug-amino acid conjugate; the small molecule drug-amino acid conjugate and an activated ester containing an R4 group undergo a nucleophilic substitution reaction to prepare the amino acid modified small molecule drug.
7. The method for preparing the brush-like polymer drug delivery system according to claim 4, characterized in that: The preparation method of the polybetaine polymer comprises the following steps: a chain transfer reagent, an azobisisobutyronitrile initiator and a betaine monomer are used to react to obtain a second intermediate, or a chain transfer reagent, an azobisisobutyronitrile initiator, a functional monomer containing an R6 group and a betaine monomer are used to react to obtain a second intermediate; after the second intermediate is subjected to n-propylamine to remove the thiocarbonyl group, an addition reaction is carried out with a methacrylate compound containing an R5 group to prepare the polybetaine polymer.
8. Use of the brush-like polymer drug delivery system according to any one of claims 1 to 3 in the preparation of drugs for treating diseases.
9. Use of the brush-like polymer drug delivery system according to any one of claims 1 to 3 in the preparation of disease prevention drugs.
